Selected Innovative Medicines in Development as of October 13, 2026

J&J

Oncology (1 of 3)

DARZALEX (daratumumab)
Frontline multiple myeloma transplant ineligible (CEPHEUS)

RYBREVANT (amivantamab)
Head and Neck Cancer (ORIGAMI-4)

TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)

TECVAYLI (teclistamab)
Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

CARVYKTI (Ciltacabtagene autoleucel)
Frontline Multiple Myeloma TNI (CARTITUDE-5)

erda-iDRS (erdafitinib intravesical delivery system)
High Risk Non Muscle Invasive Bladder Cancer (MoonRISe-3)

INLEXZO (gemcitabine intravesical delivery system)
Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

pasritamig
Metastatic Castration-Resistant Prostate Cancer (KLK2-comPAS)

INLEXZO (gemcitabine intravesical delivery system)
Non Muscle Invasive Bladder Cancer (SunRISe-1)

TALVEY + TECVAYLI
Relapsed Refractory Multiple Myeloma (RedirecTT-1)

TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

bleximenib
Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine (cAMeLot-2)

CARVYKTI (Ciltacabtagene autoleucel)
Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

ERLEADA (apalutamide)
Localized Prostate Cancer (ATLAS)

INLEXZO (gemcitabine intravesical delivery system)
High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)

pasritamig
Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger)

RYBREVANT (amivantamab)
Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

TALVEY + TECVAYLI
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

TECVAYLI (teclistamab)
Multiple Myeloma 1-3PLs (MajesTEC-3)

bleximenib
Acute Myeloid Leukemia (cAMeLot-3)

erda-iDRS (erdafitinib intravesical delivery systen
Non Muscle Invasive Bladder Cancer (MoonRISe-1)

ERLEADA (apalutamide)
High Risk Prostate Cancer (PROTEUS)

JNJ-1900 (NBTXR3)
Head and Neck Cancer Platinum Ineligible

ramantamig
Relapsed Refractory Multiple Myeloma (TRIlogy-4)

Oncology (2 of 3)

ramantamig
Relapsed Refractory Multiple Myeloma (TRIlogy-5)

RYBREVANT (amivantamab)
Colorectal Cancer 2L (ORIGAMI-3)

TECVAYLI (teclistamab)
TE NDMM maintenance (MajesTEC-4)

JNJ-0683 (ARX788)
Breast Cancer

JNJ-1493
Hematological Malignancies

JNJ-2175
Solid Tumors

JNJ-3413
Lymphoma

JNJ-4916
Lung Cancer

ramantamig
TIE NDMM in combination with Daratumumab (TRIlogy-7)

RYBREVANT (amivantamab)
Head and Neck Cancer (ORIGAMI-5)

TECVAYLI (teclistamab)
TIE NDMM in combination with DR (MajesTEC-7)

JNJ-1900 (NBTXR3)
Lung Cancer

JNJ-1900 (NBTXR3)
Head and Neck Cancer Platinum Eligible

JNJ-2638
Gastrointestinal Cancer

JNJ-4306
Hematological Malignancies

JNJ-6143 (HLD-0915)
Prostate Cancer

RYBREVANT (amivantamab)
Colorectal Cancer (ORIGAMI-2)

TALVEY (talquetamab)
TIE NDMM in combination with DR (MajesTEC-7)

bleximenib
Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)

JNJ-0387
Solid Tumors

JNJ-1981 ER (Cisplatin Extended Release)
Solid Tumors

JNJ-2761
Multiple Myeloma

JNJ-4362 (HLD-0117)
Breast Cancer

JNJ-6692
Hematological Malignancies

Oncology (3 of 3)

JNJ-7446
Lung Cancer

JNJ-8111
Prostate Cancer

JNJ-8177 (ARX517)
Prostate Cancer

JNJ-8377
Lymphoma

JNJ-9401
Prostate Cancer

JNJ-9892
Hematological Malignancies

JNJ-9968
Hematological Malignancies

Immunology

ICOTYDE (icotrokinra)
Psoriasis (ICONIC)

STELARA (ustekinumab)
Pediatric Juvenile Psoriatic Arthritis (PSUMMIT JR)

icotrokinra
Psoriatic Arthritis (ICONIC-PsA)

nipocalimab
Systemic Lupus Erythematosus (GARDENIA)

nipocalimab
Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)

icotrokinra
Crohn's Disease (ICONIC-CD)

nipocalimab
Idiopathic Inflammatory Myopathy

JNJ-8638 (Oral FcRn)
Immunological Diseases

IMAAVY (nipocalimab)
Warm Autoimmune Hemolytic Anemia (ENERGY)

TREMFYA (guselkumab)
Pediatric Juvenile Psoriatic Arthritis

JNJ-4804 Co-antibody Therapy
Ulcerative Colitis

nipocalimab
Sjogren's Disease (DAFFODIL)

TREMFYA (guselkumab)
Pediatric Crohn's Disease (MACARONI-23)

JNJ-4804 Co-antibody Therapy
Psoriatic Arthritis

JNJ-5108
Immunological Diseases

STELARA (ustekinumab)
Pediatric Ulcerative Colitis (UNIFI JR)

icotrokinra
Ulcerative Colitis (ICONIC-UC)

JNJ-4804 Co-antibody Therapy
Crohn's Disease

nipocalimab
Hemolytic Disease of the Fetus and Newborn (AZALEA)

TREMFYA (guselkumab)
Pediatric Ulcerative Colitis (QUASAR JR)

JNJ-7528
Atopic Dermatitis

JNJ-6848
Immunological Diseases

J&J

Neuroscience

CAPLYTA (lumateperone)
Adjunctive Treatment for Major Depressive Disorder

seltorexant
Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms (OARS)

ITI-1284
Alzheimer's Disease-Related Psychosis

JNJ-5120
Major Depressive Disorder

CAPLYTA (lumateperone)
Bipolar Mania

SPRAVATO (esketamine)
Major Depressive Disorder with Suicidal Ideation
Pediatrics

ITI-1284
Alzheimer's Disease-Related Agitation

CAPLYTA (lumateperone)
Pediatric Psychiatric Indications

ITI-1284
Generalized Anxiety Disorder

JNJ-2056 (tau active immunotherapy) [1]
Alzheimer's Disease (RETAIN)

Select Other Areas

UPTRAVI (selexipag)
Pediatric Pulmonary Arterial Hypertension (SALTO)

macitentan
Pulmonary Arterial Hypertension 75mg (UNISUS)

milvexian (Factor Xla)
Secondary Stroke Prevention

milvexian (Factor Xla)
Atrial Fibrillation

SIRTURO
Leprosy

SIRTURO
Tuberculosis Long Acting

[1]AC Immune ACI-35.030.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of October 13, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: AC Immune SA; SPRAVATO: Icahn School of Medicine at Mount Sinai, National Institutes of Health & Yale University; CAPLYTA: Bristol Myers Squibb; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sload Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; LAZCLUZE: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); JNJ-5120: Contineum Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited

J&J